A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

Phase 2 Completed 51 enrolled Millennium Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindOther

The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).

Evaluation	Drug	Modality	Dose	Route
Comparator	Metoclopramide	Small molecule	10 mg	Oral
Subject	Trazpiroben	Small molecule	5 mg	Oral
Subject	Trazpiroben	Small molecule	25 mg	Oral
Subject	Trazpiroben	Small molecule	100 mg	Oral